Company: ABUS
Filing Date: 2025-05-14
Form Type: 10-Q
Source: 0001447028-25-000099
Chunk: 21

Company: Arbutus Biopharma Corp
Filing Date: 2025-05-14
Form: 10-Q
Item: Part I, Item 1
Chunk 21
---
10,524 Three Months Ended March 31, 2024$7,600 $180 $7,780 

See Note 4 for additional information regarding the fair value of the Company’s investments in marketable securities. 

 9

4.    Investments in marketable securities 

Investments in marketable securities consisted of the following:Amortized CostGross Unrealized Gain(1)Gross Unrealized Loss(1)Fair ValueAs of March 31, 2025(in thousands)Cash equivalentsMoney market$23,890 $— $— $23,890 US treasury bills$2,487 $— $— $2,487 Total$26,377 $— $— $26,377 Investments in marketable short-term securitiesUS corporate bonds19,141 22 (3)19,160 US treasury bills56,470 3 (2)56,471 Total$75,611 $25 $(5)$75,631  (1) Gross unrealized gain (loss) is pre-tax and is reported in accumulated other comprehensive loss. Amortized CostGross Unrealized Gain(1)Gross Unrealized Loss(1)Fair ValueAs of December 31, 2024(in thousands)Cash equivalentsMoney market fund$29,533 $— $— $29,533 Total$29,533 $— $— $29,533 Investments in marketable short-term securitiesUS corporate bonds30,776 27 (6)30,797 US treasury bills55,467 29 — 55,496 Total$86,243 $56 $(6)$86,293 (1) Gross unrealized gain (loss) is pre-tax and is reported in accumulated other comprehensive loss.The contractual term to maturity of the $75.6 million of short-term marketable securities held by the Company as of March 31, 2025 is less than one year. As of March 31, 2025, the Company held no long-term marketable securities with contractual maturities of more than one year, but less than five years.  As of December 31, 2024, the Company’s $86.3 million of short-term marketable securities had contractual maturities of less than one year, while the Company held no